Biomunex signs licensing agreement with Sanofi for development of antibodies Medical Dialogues Bureau19 Jan 2019 3:45 AM GMTUnder the terms of the agreement, Sanofi will have access to Biomunex proprietary technology to generate and optimize bi- and multi-specific antibody t...
Sanofi to pay Regeneron $462 million in revised immuno-oncology deal Farhat Nasim9 Jan 2019 3:45 AM GMTSanofi will pay Regeneron $462 million representing the balance of payments due under their original deal, which covers the Sanofi share of the immuno-...
Merck to acquire Rigontec, RIG-I therapeutics pioneer, advancing leadership in Immuno-Oncology Ruby Khatun Khatun9 Sep 2017 4:27 AM GMTKENILWORTH, N.J. & MUNICH: Merck, known as MSD outside the United States and Canada, and Rigontec announced that Merck will acquire...
